American College of Cardiology

American College of Cardiology

Source: Late-Breakers. Published on Jan. 25, 2022. Accessed on Jan. 25, 2022.
January 26, 2022
1 min read

ACC 2022 late-breaking trials to address cardiomyopathy, acute MI, flu vaccine and more

Source: Late-Breakers. Published on Jan. 25, 2022. Accessed on Jan. 25, 2022.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The virtual 2022 American College of Cardiology Scientific Session will be held from April 2 to 4, and will feature 25 late-breaking clinical trials, 10 featured clinical research presentations and numerous abstract presentations.

The virtual ACC Scientific Sessions will also include two deep-dive sessions meant to provide further insight into the late-breaking clinical trials.

Source: Adobe Stock

The ACC announced that late-breaking science to be presented at the session includes:

  • the VALOR-HCM trial, which assessed mavacamten (Bristol Myers Squibb) as an alternative to surgical septal myectomy or alcohol ablation for patients with severe symptomatic obstructive hypertrophic cardiomyopathy (HCM);
  • the double-blind PACMAN AMI trial of the effects of alirocumab (Praluent, Sanofi/Regeneron) on coronary atherosclerosis assessed by serial multimodality intracoronary imaging in patients with acute MI;
  • the double-blind APOLLO trial that evaluated the effects of a short-interfering RNA-targeting lipoprotein(a);
  • IVVE, a randomized trial to assess the effects of influenza vaccination on vascular events;
  • the PROMPT-HF trial, which sought to improve use of guideline-directed medical therapies among outpatients with HF;
  • updated results of treatment from the EXPLORER-LTE cohort of the MAVALTE study in patients with obstructive HCM;
  • the 1-year results of the Clasp TR trial that evaluated transcatheter treatment of tricuspid regurgitation (Pascal, Edwards Lifesciences);
  • the ADAPT-TAVR trial that compared edoxaban (Savaysa, Daiichi Sankyo) with dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism following transcatheter aortic valve replacement;
  • the FLAVOUR trial which compared fractional flow reserve with IVUS-guided PCI for intermediate coronary artery stenosis; and
  • the GIPS-IV trial which tested the feasibility of sodium thiosulfate for the preservation of cardiac function after STEMI.

Other late breaking trials to be presented include SODIUM-HF, POISE-3, MITIGATE, TRANSLATE-TIMI 70, SuperWIN, METEORIC-HF, DIAMOND, PROTECT, insights from the Corevalve U.S. Pivotal and SURTAVI trials, GHATI and BIO|GUARD-MI.

The meeting will also showcase two featured clinical research sessions, highlighting a total of 10 individual trials.

Cardiology Today and Healio will be reporting news from the virtual ACC Scientific Session. Stay tuned for news, perspectives and more. Also follow @CardiologyToday on Twitter for continuing updates.